疼痛，是阿飞童年乃至青年时期最深刻的记忆。从10岁那年起，他的手脚便莫名疼痛，皮肤像被烈火灼 烧，痛感时而持续几小时，时而绵延数日，毫无规律可循。病情发作不知何时到来，也不知何时才能停 歇。 中国首款法布雷病基因治疗药物 ——患法布雷病的四川小伙讲述与病魔抗争的故事 "成都造"基因药有望实现一次注射长期有效。 从10岁被莫名剧痛缠上，到18岁终获确诊，他等了8年；从确诊时被告知"无药可医"，到用上对症药 物，他又等了7年。15年光阴，四川小伙阿飞在法布雷病的"灼烧感"和"无法排汗"中艰难前行。 2026年2月28日，是第19个国际罕见病日。华西都市报、封面新闻记者采访了法布雷病患者阿飞，倾听 他与罕见病抗争的故事。 罕见病是指"新生儿发病率小于万分之一、患病率小于万分之一"的疾病。法布雷病作为罕见病中的一 种，引发剧烈疼痛、肾功能损伤、心脏病变等一系列症状，严重时可危及生命。 皮肤像被火烧 8年辗转终得一个确诊 ZS805注射液计划2028年上市。受访者供图 "发作起来，痛得根本没法睡觉，浑身冒冷汗，有时候甚至痛到打滚。"阿飞说，小时候的他，吃止痛 药、打止痛针成了家常便饭，即便药效甚微，那也是他对抗疼痛的唯 ...

Core Insights - Rui Jian Pharmaceutical has achieved significant milestones in the development of its Parkinson's disease cell therapy product NouvNeu001, becoming the first globally to receive Fast Track designation from the FDA and entering Phase II clinical trials in China [1][4] - Chengdu High-tech Zone is emerging as a key player in the biopharmaceutical industry, with a focus on innovative drug development and a robust ecosystem supporting various companies [3][12] Company Developments - Rui Jian Pharmaceutical's NouvNeu001 is the first iPSC-derived universal cell therapy for Parkinson's disease to gain Fast Track status from the FDA, while also progressing in clinical trials in China [1] - The company is also advancing other products, such as NouvNeu004 for multiple system atrophy, which has received approval for full-cycle clinical trials in China [4] - Recent funding of over 300 million yuan for Rui Jian Pharmaceutical will accelerate the development of its Parkinson's and ophthalmic treatment products [14] Industry Trends - Chengdu High-tech Zone has been recognized as a leading biopharmaceutical hub, ranking alongside other major innovation districts in China [3] - The region is witnessing a surge in innovative products, with multiple companies achieving significant breakthroughs in various therapeutic areas, including diabetes and cancer [7][5] - The biopharmaceutical industry in Chengdu is projected to exceed 128 billion yuan in scale by 2024, with over 3,000 companies contributing to this growth [7] Ecosystem and Collaboration - The development of Rui Jian Pharmaceutical is closely tied to the supportive ecosystem in Chengdu High-tech Zone, which includes a network of suppliers and clinical resources [8][10] - The establishment of the "Global New Drug Discovery Center" aims to integrate resources from over 3,000 biopharmaceutical companies in the region, enhancing collaboration and innovation [11] - The collaboration between enterprises and institutions, such as Sichuan University West China Hospital, is fostering a comprehensive innovation chain from research to commercialization [12][18] Policy and Financial Support - Chengdu High-tech Zone has implemented supportive policies and established a substantial investment fund to facilitate the growth of the biopharmaceutical sector [16][17] - The "Wutong Plan" provides a comprehensive service framework for biopharmaceutical companies, covering all stages from drug development to market entry [17] - The region's proactive approach in policy-making and capital investment is crucial in overcoming challenges in the biopharmaceutical innovation landscape [16][14]